Rapid detection and differentiation of clinically relevant candida species simultaneously from blood culture by use of a novel signal amplification approach

Wanyuan Ao, Joshua Klonoski, Eric Berlinghoff, Jordan Jensen, Taliman Afroz, Denton Munns, Wes Lindsey, Gerald Denys, Robert Jenisona

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fungal bloodstream infections are a significant problem in the United States, with an attributable mortality rate of up to 40%. An early diagnosis to direct appropriate therapy has been shown to be critical to reduce mortality rates. Conventional phenotypic methods for fungal detection take several days, which is often too late to impact outcomes. Herein, we describe a cost-effective multiplex assay platform for the rapid detection and differentiation of major clinically relevant Candida species directly from blood culture. This approach utilizes a novel biotin-labeled polymer-mediated signal amplification process combined with targeting rRNA to exploit phylogenetic differences for sensitive and unambiguous species identification; this assay detects seven pathogenic Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, and C. guilliermondii) simultaneously with very high specificity to the species level in less than 80 min with the limits of detection at 1 103 to 10 103 CFU/ml or as few as 50 CFU per assay. The performance of the described assay was verified with 67 clinical samples (including mixed multiple-species infections as well), with an overall 100% agreement with matrix-assisted laser desorption ionization (MALDI) mass spectrometry-based reference results. By providing a species identity rapidly, the clinician is aided with information that may direct appropriate therapy sooner and more accurately than current approaches, including PCR-based tests.

Original languageEnglish (US)
Article numbere00982
JournalJournal of clinical microbiology
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Candida
Species Specificity
Mortality
Mycoses
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Biotin
Limit of Detection
Early Diagnosis
Polymers
Costs and Cost Analysis
Polymerase Chain Reaction
Therapeutics
Infection
Blood Culture

Keywords

  • AMPED
  • Blood culture
  • Candida
  • Candida detection
  • Molecular diagnostics
  • Signal amplification

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Rapid detection and differentiation of clinically relevant candida species simultaneously from blood culture by use of a novel signal amplification approach. / Ao, Wanyuan; Klonoski, Joshua; Berlinghoff, Eric; Jensen, Jordan; Afroz, Taliman; Munns, Denton; Lindsey, Wes; Denys, Gerald; Jenisona, Robert.

In: Journal of clinical microbiology, Vol. 56, No. 1, e00982, 01.01.2018.

Research output: Contribution to journalArticle

Ao, Wanyuan ; Klonoski, Joshua ; Berlinghoff, Eric ; Jensen, Jordan ; Afroz, Taliman ; Munns, Denton ; Lindsey, Wes ; Denys, Gerald ; Jenisona, Robert. / Rapid detection and differentiation of clinically relevant candida species simultaneously from blood culture by use of a novel signal amplification approach. In: Journal of clinical microbiology. 2018 ; Vol. 56, No. 1.
@article{c5a8e061db09484e9a25f39b29026c09,
title = "Rapid detection and differentiation of clinically relevant candida species simultaneously from blood culture by use of a novel signal amplification approach",
abstract = "Fungal bloodstream infections are a significant problem in the United States, with an attributable mortality rate of up to 40{\%}. An early diagnosis to direct appropriate therapy has been shown to be critical to reduce mortality rates. Conventional phenotypic methods for fungal detection take several days, which is often too late to impact outcomes. Herein, we describe a cost-effective multiplex assay platform for the rapid detection and differentiation of major clinically relevant Candida species directly from blood culture. This approach utilizes a novel biotin-labeled polymer-mediated signal amplification process combined with targeting rRNA to exploit phylogenetic differences for sensitive and unambiguous species identification; this assay detects seven pathogenic Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, and C. guilliermondii) simultaneously with very high specificity to the species level in less than 80 min with the limits of detection at 1 103 to 10 103 CFU/ml or as few as 50 CFU per assay. The performance of the described assay was verified with 67 clinical samples (including mixed multiple-species infections as well), with an overall 100{\%} agreement with matrix-assisted laser desorption ionization (MALDI) mass spectrometry-based reference results. By providing a species identity rapidly, the clinician is aided with information that may direct appropriate therapy sooner and more accurately than current approaches, including PCR-based tests.",
keywords = "AMPED, Blood culture, Candida, Candida detection, Molecular diagnostics, Signal amplification",
author = "Wanyuan Ao and Joshua Klonoski and Eric Berlinghoff and Jordan Jensen and Taliman Afroz and Denton Munns and Wes Lindsey and Gerald Denys and Robert Jenisona",
year = "2018",
month = "1",
day = "1",
doi = "10.1128/JCM.00982-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Rapid detection and differentiation of clinically relevant candida species simultaneously from blood culture by use of a novel signal amplification approach

AU - Ao, Wanyuan

AU - Klonoski, Joshua

AU - Berlinghoff, Eric

AU - Jensen, Jordan

AU - Afroz, Taliman

AU - Munns, Denton

AU - Lindsey, Wes

AU - Denys, Gerald

AU - Jenisona, Robert

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Fungal bloodstream infections are a significant problem in the United States, with an attributable mortality rate of up to 40%. An early diagnosis to direct appropriate therapy has been shown to be critical to reduce mortality rates. Conventional phenotypic methods for fungal detection take several days, which is often too late to impact outcomes. Herein, we describe a cost-effective multiplex assay platform for the rapid detection and differentiation of major clinically relevant Candida species directly from blood culture. This approach utilizes a novel biotin-labeled polymer-mediated signal amplification process combined with targeting rRNA to exploit phylogenetic differences for sensitive and unambiguous species identification; this assay detects seven pathogenic Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, and C. guilliermondii) simultaneously with very high specificity to the species level in less than 80 min with the limits of detection at 1 103 to 10 103 CFU/ml or as few as 50 CFU per assay. The performance of the described assay was verified with 67 clinical samples (including mixed multiple-species infections as well), with an overall 100% agreement with matrix-assisted laser desorption ionization (MALDI) mass spectrometry-based reference results. By providing a species identity rapidly, the clinician is aided with information that may direct appropriate therapy sooner and more accurately than current approaches, including PCR-based tests.

AB - Fungal bloodstream infections are a significant problem in the United States, with an attributable mortality rate of up to 40%. An early diagnosis to direct appropriate therapy has been shown to be critical to reduce mortality rates. Conventional phenotypic methods for fungal detection take several days, which is often too late to impact outcomes. Herein, we describe a cost-effective multiplex assay platform for the rapid detection and differentiation of major clinically relevant Candida species directly from blood culture. This approach utilizes a novel biotin-labeled polymer-mediated signal amplification process combined with targeting rRNA to exploit phylogenetic differences for sensitive and unambiguous species identification; this assay detects seven pathogenic Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. lusitaniae, and C. guilliermondii) simultaneously with very high specificity to the species level in less than 80 min with the limits of detection at 1 103 to 10 103 CFU/ml or as few as 50 CFU per assay. The performance of the described assay was verified with 67 clinical samples (including mixed multiple-species infections as well), with an overall 100% agreement with matrix-assisted laser desorption ionization (MALDI) mass spectrometry-based reference results. By providing a species identity rapidly, the clinician is aided with information that may direct appropriate therapy sooner and more accurately than current approaches, including PCR-based tests.

KW - AMPED

KW - Blood culture

KW - Candida

KW - Candida detection

KW - Molecular diagnostics

KW - Signal amplification

UR - http://www.scopus.com/inward/record.url?scp=85040030791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040030791&partnerID=8YFLogxK

U2 - 10.1128/JCM.00982-17

DO - 10.1128/JCM.00982-17

M3 - Article

C2 - 29046411

AN - SCOPUS:85040030791

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

M1 - e00982

ER -